Division of Pharmacoepidemiology, @BrighamWomens @HarvardMed • Director @akesselheim
Joined October 2014
- Tweets 4,503
- Following 1,084
- Followers 2,686
- Likes 3,362
994 Photos and videos
We're excited to share that the PORTAL has been selected by @statnews to compete in this year's #STATMadness for our research on pharmaceutical device patents! 🏆🏀
Help us get to the next round by voting for PORTAL (Brigham and Women's Hospital) here: statnews.com/feature/stat-ma…
3
191
Check out the latest from PORTAL in the October edition of the PORTAL Post newsletter - mailchi.mp/b6a7308443ff/port…
1
3
443
Check out the latest research from the PORTAL team in the summer edition of our PORTAL Post newsletter - mailchi.mp/9a32b4317ef2/port…
1
2
250
Out now from Dr. Jerry Avorn— RETHINKING MEDICATIONS: Truth, Power, and the Drugs You Take
In his new book, Dr. Avorn explains why some medications are poorly evaluated, overpriced, or pose unwarranted risks—and how we fix that.
Grab a copy today: rethinkmeds.info
ALT "Rethinking Medications: Truth, Power, and the Drugs You Take," by Jerry Avorn, MD - https://rethinkmeds.info/
1
4
647
Program On Regulation, Therapeutics, And Law retweeted
23 Apr 2025
Excited to get this brand new book by Jerry Avorn from @PORTAL_Research in the mail today! Can't wait to give it a read!
@BrighamWomens @harvardmed
2
3
456
WATCH: @akesselheim's testimony yesterday before @WaysMeansCmte
On NIH cuts - "...the next generation will look back at this moment & ask what we were doing while the Trump administration systematically disposed of 1000s of research projects that could've helped patients."
1
2
6
341
And, on strategies to improve the biosimilar market, including by implementing policies to facilitate biosimilar interchangeability, clear patent thickets, and preventing biosimilar rebate gaming by PBMs.
1
2
4
320
View his full testimony before the Health Subcommittee: waysandmeans.house.gov/event…
Read his written testimony: waysandmeans.house.gov/wp-co…
1
110
Program On Regulation, Therapeutics, And Law retweeted
8 Apr 2025
Happening now: @WaysandMeansGOP hearing on lowering costs for patients: The health of the biosimilar market featuring @PORTAL_Research’s @akesselheim. Watch here: bit.ly/3YqiXzV
1
1
6
621
Tune in TODAY at 10am ET as PORTAL Director Aaron Kesselheim testifies before the House Ways & Means Health Subcommittee: youtu.be/x_rhGT9AM0k
He'll be discussing threats to US biomedical research, the need to protect and expand Medicare drug price negotiation, and more.
1
360
Program On Regulation, Therapeutics, And Law retweeted
30 Dec 2024
I'm excited to share a new study out today @bmj_latest comparing the two single-inhaler triple therapies on the US market.
Brief thread below!
bmj.com/content/387/bmj-2024…
3
6
14
2,925
Program On Regulation, Therapeutics, And Law retweeted
19 Dec 2024
Published today in @JAMAOnc with @akesselheim and @PORTAL_Research team.
We discuss the case of cancer drug Xtandi whose early stage developments were heavily funded by government grants and public funds but now is priced more in the U.S. than in other high-income countries.
jamanetwork.com/journals/jam…
1
4
30
5,304
Program On Regulation, Therapeutics, And Law retweeted
28 Oct 2024
Presenting some work on QALY-based cost-effectiveness analyses at #SMDM24 that shows some arguments against the use of QALYs have little empirical justification.
@PORTAL_Research
2
5
30
1,926
Program On Regulation, Therapeutics, And Law retweeted
22 Oct 2024
💊 New study in JAMA provides clear steps busy clinicians & staff can take to help patients struggling to afford their prescription drugs!
We include an algorithm based on the patient's health insurance status & drug type (brand vs. generic).
READ: jamanetwork.com/journals/jam…
21 Oct 2024
This article describes strategies that clinical teams can use to help patients afford prescription drugs and proposes an algorithm to help identify which strategies may be most helpful based on insurance status and type of drug.
ja.ma/48i796p
3
22
49
17,556
Interested in the strategies and tools clinicians can use to help their patients afford prescription drugs?
Check out this new overview in @JAMA by @DrHussainL, Catherine Hwang, @bnrome, and @akesselheim highlighting the options available to patients.
21 Oct 2024
This article describes strategies that clinical teams can use to help patients afford prescription drugs and proposes an algorithm to help identify which strategies may be most helpful based on insurance status and type of drug.
ja.ma/48i796p
3
6
525
The federal government has proven that it can navigate the difficult process of identifying drugs for price negotiation, gathering and analyzing key information, and negotiating with manufacturers. Read the full Perspective: nej.md/48711hx
ALT There is now a clear pathway for leveraging federal price negotiation to substantially lower spending and translate associated savings into reduced out-of-pocket costs for Part D beneficiaries. Perspective Benjamin N. Rome, M.D., M.P.H., Aaron S. Kesselheim, M.D., J.D., M.P.H., and William B. Feldman, M.D., D.Phil., M.P.H.
3
6
11,173
In order to ensure timely testing of drugs that have been granted accelerated approval, the FDA can impose civil monetary penalties on dilatory manufacturers — but has never done so. Read the full Perspective: nej.md/3BvjsAe
ALT The FDA’s core mission is not ensuring the financial stability of pharmaceutical manufacturers that choose to avail themselves of a regulatory pathway and then fail to meet its requirements. Perspective C. Joseph Ross Daval, J.D., Aaron S. Kesselheim, M.D., J.D., M.P.H., and Edward R. Scheffer Cliff, M.B., B.S., M.P.H.
10
20
16,056
Program On Regulation, Therapeutics, And Law retweeted
7 Oct 2024
Despite the Pediatric Research Equity Act, which applied to only 30% of new drugs approved 2015-2021, >50% of required postmarketing pediatric trials remain incomplete after 5.5 years, highlighting the impact of rare disease exemptions. ja.ma/4gO3xgF
2
5
5,673